The first study results of the combination of ADC and PD-1 inhibitors as first-line treatment for ES-SCLC have been announced.

Professor Zhou Caicun from Tongji University affiliated Oriental Hospital led a Phase II clinical trial of a novel anti-PD-1 monoclonal antibody Iza-Bren in the first-line treatment of extensive-stage small cell lung cancer, achieving positive results. The study demonstrated that the combination of ADC with PD-1 inhibitor as first-line therapy for ES-SCLC yielded promising results, potentially establishing a new treatment standard. At a dosage of iza-bren 2.5 mg/kg D1D8 Q3W, the combination therapy with Sulumab achieved the longest median progression-free survival (PFS) of 8.2 months and a 1-year overall survival (OS) rate of 85.7%.